Fibronectin is a serum biomarker for Duchenne muscular dystrophy
Version of Record online: 11 MAR 2014
© 2014 The Authors PROTEOMICS – Clinical Applications Published by Wiley-VCH Verlag GmbH & Co. KGaA
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
PROTEOMICS - Clinical Applications
Focus on Proteomics and the Eye
Volume 8, Issue 3-4, pages 269–278, April 2014
How to Cite
Cynthia Martin, F., Hiller, M., Spitali, P., Oonk, S., Dalebout, H., Palmblad, M., Chaouch, A., Guglieri, M., Straub, V., Lochmüller, H., Niks, E. H., Verschuuren, J. J. G. M., Aartsma-Rus, A., Deelder, A. M., van der Burgt, Y. E. M. and 't Hoen, P. A. C. (2014), Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Prot. Clin. Appl., 8: 269–278. doi: 10.1002/prca.201300072
- Issue online: 13 APR 2014
- Version of Record online: 11 MAR 2014
- Accepted manuscript online: 23 JAN 2014 09:47PM EST
- Manuscript Accepted: 17 NOV 2013
- Manuscript Revised: 5 NOV 2013
- Manuscript Received: 6 AUG 2013
- European Union Seventh Framework Programme. Grant Number: 241665
- “Biomarkers for neuromuscular disorders”. Grant Number: 305121
- NEUROMICS. Grant Number: 305444
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supplementary Figure 1: (A) A representative example of a 1D SDS PAGE (Tris-Glycine 4–20% gradient gel) of four different serum pools with and without ProteoMinerTM workup. From left to right, protein markers (M) from 10–170 kDa, ProteoMinerTM eluates (E) from the adult control group (E1), child control group (E2), DMD ambulant group (E3) and DMD non-ambulant group (E4), and four corresponding flow through fractions. The eluate fractions were cut into ten pieces and were in-gel digested using trypsin or Lys-N. The band at 67 kDa represents albumin, which was strongly depleted in the eluates.
(B) Reproducibility of ProteoMinerTM was evaluated by loading a serum sample on four separate ProteoMinerTM columns. Eluates from the four columns are marked as 1–4.
|prca1520-sup-0002-FigureS2.pdf||70K||Supplementary Figure 2: Peptide ID iProphet scores (1-P) plotted on a logarithmic scale.The peptide numbers in Figure 2 are based on iProphet probability values between 1 and 0.20.The lowest numbers correspond to the highest confidence levels. A = CID tryptic peptides; B = ETD tryptic peptides; C = CID Lys-N peptides; D = ETD Lys-N peptides.|
|prca1520-sup-0003-FigureS3.pdf||34K||Supplementary Figure 3: Serum fibronectin levels plotted as function of age in ambulant (crosses) and non-ambulant (circles) DMD patients.|
|prca1520-sup-0004-FigureS4.jpg||39K||Supplementary Figure 4: Serum fibronectin levels (left y-axis; blue diamonds) and CK activity measurements (right y-axis, red circles) are plotted as a function of age for the longitudinal DMD cohort.|
|prca1520-sup-0005-TableS1.pdf||63K||Supplementary Table 1: Number of peptides and proteins identified through the different digestion and fragmentation strategies.|
|prca1520-sup-0006-TableS2.pdf||56K||Supplementary Table 2: List of proteins with ≥ 2 unique peptides per protein identified (validated by ProteinProphet) from trypsin and Lys-N digestion with CID and ETD fragmentation across all four groups. The table includes protein name, molecular weight and number of spectral counts.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.